Systemic antibiotics cause deterioration of emphysema associated with exaggerated inflammation and autophagy.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
08
01
2023
accepted:
16
07
2023
revised:
30
06
2023
medline:
2
11
2023
pubmed:
2
10
2023
entrez:
1
10
2023
Statut:
ppublish
Résumé
The interaction between the microbial environment and the host is important for immune homeostasis. Recent research suggests that microbiota dysbiosis can be involved in respiratory diseases. Emphysema is a chronic inflammatory disease, but it is unclear whether dysbiosis caused by antibiotics can affect disease progression. Here, we tried to elucidate the effect of systemic antibiotics on smoking-exposed emphysema models. In this study, the antibiotic mixture caused more alveolar destruction and airspace expansion in the smoking group than in the smoking only or control groups. This emphysema aggravation as a result of antibiotic exposure was associated with increased levels of inflammatory cells, IL-6, IFNγ and protein concentrations in bronchoalveolar lavage fluid. Proteomics analysis indicated that autophagy could be involved in antibiotic-associated emphysema aggravation, and increased protein levels of LC3B, atg3, and atg7 were identified by Western blotting. In microbiome and metabolome analyses, the composition of the gut microbiota was different with smoking and antibiotic exposure, and the levels of short-chain fatty acids (SCFAs), including acetate and propionate, were reduced by antibiotic exposure. SCFA administration restored emphysema development with reduced inflammatory cells, IL-6, and IFNγ and decreased LC3B, atg3, and atg7 levels. In conclusion, antibiotics can aggravate emphysema, and inflammation and autophagy may be associated with this aggravation. This study provides important insight into the systemic impact of microbial dysbiosis and the therapeutic potential of utilizing the gut microbiota in emphysema.
Identifiants
pubmed: 37779147
doi: 10.1038/s12276-023-01099-6
pii: 10.1038/s12276-023-01099-6
pmc: PMC10618248
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2260-2268Informations de copyright
© 2023. The Author(s).
Références
J Cell Mol Med. 2014 Jan;18(1):15-26
pubmed: 24256364
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9
pubmed: 21402903
J Clin Med. 2018 Sep 14;7(9):
pubmed: 30223529
Thorax. 2012 Nov;67(11):957-63
pubmed: 22684094
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Lung. 2008 May-Jun;186(3):167-172
pubmed: 18330638
Nat Med. 2016 Oct;22(10):1187-1191
pubmed: 27618652
Nat Commun. 2015 Jun 23;6:7320
pubmed: 26102221
Ann Am Thorac Soc. 2016 Dec;13 Suppl 2:S466-S470
pubmed: 28005422
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893867
Acta Biomed. 2021 Jul 01;92(3):e2021165
pubmed: 34212932
Inflamm Bowel Dis. 2010 Feb;16(2):347-53
pubmed: 19572377
J Proteome Res. 2018 Sep 7;17(9):2917-2924
pubmed: 30114372
Nat Commun. 2019 Dec 13;10(1):5711
pubmed: 31836714
Cell Biol Toxicol. 2017 Apr;33(2):197-206
pubmed: 27744523
Infect Immun. 2005 Jan;73(1):30-8
pubmed: 15618138
Nat Med. 2014 Feb;20(2):159-66
pubmed: 24390308
Immunity. 2017 Apr 18;46(4):549-561
pubmed: 28423336
Respirology. 2017 Apr;22(3):575-601
pubmed: 28150362
Eur Respir J. 2006 Apr;27(4):689-96
pubmed: 16585077
Exp Mol Med. 2020 Jul;52(7):1128-1139
pubmed: 32681029
Eur Respir J. 2016 May;47(5):1357-64
pubmed: 26869671
Autophagy. 2018;14(2):221-232
pubmed: 29130366
Sci Rep. 2021 Mar 26;11(1):7008
pubmed: 33772084
Clin Exp Allergy. 2008 Apr;38(4):629-33
pubmed: 18352976
Microbes Infect. 2020 Sep;22(8):294-302
pubmed: 32305502
Redox Biol. 2020 Sep;36:101679
pubmed: 32818797
Front Immunol. 2020 Feb 14;11:207
pubmed: 32117318
EMBO Rep. 2012 May 01;13(5):440-7
pubmed: 22422004
Inflamm Bowel Dis. 2012 Jun;18(6):1092-100
pubmed: 22102318
World J Gastroenterol. 2014 Oct 7;20(37):13501-11
pubmed: 25309080
Cell Host Microbe. 2017 Nov 8;22(5):697-704.e4
pubmed: 29120746
PLoS One. 2019 Jun 18;14(6):e0218384
pubmed: 31211803
Immunity. 2012 Jul 27;37(1):158-70
pubmed: 22705104
Mucosal Immunol. 2018 May;11(3):785-795
pubmed: 29067994
Nucleic Acids Res. 2000 Jan 1;28(1):45-8
pubmed: 10592178
Nat Immunol. 2019 Oct;20(10):1279-1290
pubmed: 31501577
Am Rev Respir Dis. 1977 Feb;115(2):195-205
pubmed: 842934
Am J Physiol Cell Physiol. 2018 Jan 1;314(1):C73-C87
pubmed: 27413169
Science. 2012 Jun 8;336(6086):1268-73
pubmed: 22674334
Br J Gen Pract. 2021 Mar 26;71(705):e266-e272
pubmed: 33657007
Gut. 1987 Oct;28(10):1221-7
pubmed: 3678950
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
Sci Transl Med. 2017 Feb 8;9(376):
pubmed: 28179507
J Infect. 2013 Dec;67(6):497-515
pubmed: 23973659
Am Rev Respir Dis. 1989 Sep;140(3 Pt 2):S82-4
pubmed: 2782765
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S150-6
pubmed: 26595731
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795
Nat Commun. 2020 Nov 18;11(1):5886
pubmed: 33208745